Inhibition of microRNA with antisense oligonucleotides

被引：199

作者：

Esau, Christine C. ^{[1
]}

机构：

[1] Isis Pharmaceut & Regulus Therapeut, Carlsbad, CA 92008 USA

来源：

METHODS | 2008年 / 44卷 / 01期

关键词：

microRNA; antisense oligonucleotides;

D O I：

10.1016/j.ymeth.2007.11.001

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Antisense inhibition of microRNA (miRNA) function has been an important tool for uncovering miRNA biology. Chemical modification of anti-miRNA oligonucleotides (AMOs) is necessary to improve affinity for target miRNA, stabilize the AMO to nuclease degradation, and to promote tissue uptake for in vivo delivery. Here I summarize the work done to evaluate the effectiveness of various chemically modified AMOs for use in cultured cells and rodent models, and outline important issues to consider when inhibiting miRNAs with antisense oligonucleotides. (c) 2007 Elsevier Inc. All rights reserved.

引用

页码：55 / 60

页数：6

共 46 条

[1] Alicaforsen therapy in inflammatory bowel disease [J].

Barish, CF .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2005, 5 (10) :1387-1391

[2] Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation [J].

Bijsterbosch, MK ;

Rump, ET ;

De Vrueh, RLA ;

Dorland, R ;

van Veghel, R ;

Tivel, KL ;

Biessen, EAL ;

van Berkel, TJC ;

Manoharan, M .

NUCLEIC ACIDS RESEARCH, 2000, 28 (14) :2717-2725

[3] bis-cholesteryl-conjugated phosphorothioate oligodeoxynucleotides are highly selectively taken up by the liver [J].

Bijsterbosch, MK ;

Manoharan, M ;

Dorland, R ;

Van Veghel, R ;

Biessen, EAL ;

Van Berkel, TJC .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (02) :619-626

[4] Spinal distribution and metabolism of 2′-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats [J].

Butler, M ;

Hayes, CS ;

Chappell, A ;

Murray, SF ;

Yaksh, TL ;

Hua, XY .

NEUROSCIENCE, 2005, 131 (03) :705-715

[5] Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis [J].

Cheng, AM ;

Byrom, MW ;

Shelton, J ;

Ford, LP .

NUCLEIC ACIDS RESEARCH, 2005, 33 (04) :1290-1297

[6] Enhanced hepatic uptake and bioactivity of type α1(I) collagen gene promoter-specific triplex-forming oligonucleotides after conjugation with cholesterol [J].

Cheng, K ;

Ye, ZY ;

Guntaka, RV ;

Mahato, RI .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 317 (02) :797-805

[7] A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer [J].

Chi, KN ;

Eisenhauer, E ;

Fazli, L ;

Jones, EC ;

Goldenberg, SL ;

Powers, J ;

Tu, DS ;

Gleave, ME .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1287-1296

[8] Antisense strategies [J].

Crooke, ST .

CURRENT MOLECULAR MEDICINE, 2004, 4 (05) :465-487

[9] Intravitreous anti-raf-1 kinase antisense oligonucleotide as an angioinhibitory agent in porcine preretinal neovascularization [J].

Danis, DP ;

Criswell, MH ;

Orge, F ;

Wancewicz, EV ;

Stecker, K ;

Henry, SP ;

Monia, BP .

CURRENT EYE RESEARCH, 2003, 26 (01) :45-54

[10] Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications [J].

Dapic, V ;

Bates, PJ ;

Trent, JO ;

Rodger, A ;

Thomas, SD ;

Miller, DM .

BIOCHEMISTRY, 2002, 41 (11) :3676-3685

← 1 2 3 4 5 →